(Q24246777)

1

0 references

Franz Porzsolt

2

0 references

Michael Autenrieth

3

0 references

Julia Kumpf

4

0 references

Andrew Coldman

Cochrane Database of Systematic Reviews

5

0 references

publication date

19 July 2004

0 references

published in

0 references

cites work

Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Biological and clinical effects of interferon-beta ser at two doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Interferon therapy in disseminated renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of Melanoma and Renal Cell Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma Subgroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

[Advantages and problems of multicenter therapy studies exemplified by a study of the treatment of metastasizing renal cell carcinoma with recombinant interferon-alpha-2c].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Is there logic in the placebo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

The genetic basis of cancer of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Immunotherapy: the last 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Fair conduct and fair reporting of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Aldesleukin in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

21 January 2018

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

Many reports of RCTs give insufficient data for Cochrane reviewers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcom

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Cytoreductive nephrectomy: is it a realistic option in patients with renal cancer?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Recombinant interferon-alpha 2 antibodies in renal cell carcinoma. Delta-P Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Immunotherapy of metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

[Treatment of metastatic kidney cancer with recombinant alpha-2 or gamma interferon. Results of 2 clinical phase II and III studies]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Planned Equivalence or Noninferiority Trials Versus Unplanned Noninferiority Claims: Are They Equal?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425.PUB2

7 January 2021

10.1002/14651858.CD001425.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15674877

1 reference

Consolidated OpenCitations Corpus – April 2017